{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:36:01Z","timestamp":1784806561655,"version":"3.55.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.critrevonc.2022.103642","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T20:03:21Z","timestamp":1646424201000},"page":"103642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation"],"prefix":"10.1016","volume":"176","author":[{"given":"Fred H.","family":"Menko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Monkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans B.L.","family":"Hogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efraim H.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel A.","family":"Adank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle W.G.","family":"Ruijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline M.A.","family":"Bleiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester S.A.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizet E.","family":"van der Kolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2011-100380","article-title":"CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women","volume":"48","author":"Adank","year":"2011","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031128","article-title":"Genetic predisposition to breast and ovarian cancers: how many and which genes to test?","volume":"21","author":"Angeli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229999","article-title":"Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: a multi-methods study","volume":"15","author":"Archer","year":"2020","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103642_bib4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1200\/JCO.2015.65.5522","article-title":"Panel testing is not a panacea","volume":"34","author":"Axilbund","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.amjsurg.2021.03.060","article-title":"Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute","volume":"221","author":"Bagwell","year":"2021","journal-title":"Am. J. Surg."},{"issue":"34","key":"10.1016\/j.critrevonc.2022.103642_bib6","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing","volume":"34","author":"Balma\u00f1a","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ijrobp.2019.07.026","article-title":"The implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists","volume":"105","author":"Bergom","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"31","key":"10.1016\/j.critrevonc.2022.103642_bib9","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.00531","article-title":"Risk of late-onset breast cancer in genetically predisposed women","volume":"39","author":"Boddicker","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib10","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-019-13194-2","article-title":"Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2","volume":"10","author":"Boonen","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jnci\/djaa203","article-title":"Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers","volume":"113","author":"Borde","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103642_bib12","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/fon-2018-0476","article-title":"Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle","volume":"15","author":"Bowles","year":"2019","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10897-016-9985-2","article-title":"The clinical utility of next generation sequencing results in a community-based hereditary cancer risk program","volume":"26","author":"Bunnell","year":"2017","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.critrevonc.2022.103642_bib15","unstructured":"Cancer Institute NSW. eviQ [Available from: \u3008https:\/\/www.eviq.org.au\/\u3009."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","article-title":"International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer","volume":"62","author":"Canto","year":"2013","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/cge.13864","article-title":"Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers","volume":"99","author":"Cavaill\u00e9","year":"2021","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jgo.2020.11.008","article-title":"Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer","volume":"12","author":"Ch\u00e1varri-Guerra","year":"2021","journal-title":"J. Geriatr. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1086\/421251","article-title":"1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies","volume":"74","author":"CHEK2*","year":"2004","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib21","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e60","article-title":"The influence of BRCA variants of unknown significance on cancer risk management decision-making","volume":"30","author":"Chern","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103642_bib22","article-title":"Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing","volume":"3","author":"Clark","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","article-title":"Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers","volume":"182","author":"Cragun","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cncr.33357","article-title":"Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients","volume":"127","author":"Culver","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5858\/arpa.2020-0025-CP","article-title":"Laboratory and clinical implications of incidental and secondary germline findings during tumor testing","volume":"146","author":"Cushman-Vokoun","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib29","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/jmedgenet-2017-104588","article-title":"Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks","volume":"54","author":"Decker","year":"2017","journal-title":"J. Med. Genet."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib30","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdx528","article-title":"Molecular Tumor Boards: current practice and future needs","volume":"28","author":"van der Velden","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib31","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cncr.33305","article-title":"Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years","volume":"127","author":"Desai","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103642_bib33","article-title":"Expanded analysis of secondary germline findings from matched tumor\/normal sequencing identifies additional clinically significant mutations","volume":"3","author":"Dumbrava","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2022.103642_bib34","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103642_bib35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1186\/s12885-015-1934-1","article-title":"Understanding of BRCA VUS genetic results by breast cancer specialists","volume":"15","author":"Eccles","year":"2015","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib36","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","article-title":"BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance","volume":"26","author":"Eccles","year":"2015","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ijc.32396","article-title":"Breast cancer risk in BRCA1\/2 mutation carriers and noncarriers under prospective intensified surveillance","volume":"146","author":"Engel","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123762","article-title":"Germline TP53 testing in breast cancers: why, when and how?","volume":"12","author":"Evans","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmg.2009.075176","article-title":"Risk of breast cancer in male BRCA2 carriers","volume":"47","author":"Evans","year":"2010","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib40","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/s41467-020-17374-3","article-title":"Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions","volume":"11","author":"Fahed","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092415","article-title":"Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: impact of pathogenic variants in other genes beyond BRCA1\/2","volume":"12","author":"Fanale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103642_bib42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer -association with patient and disease characteristics and effect on prognosis","volume":"39","author":"Fasching","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib44","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/humu.23896","article-title":"Dutch genome diagnostic laboratories accelerated and improved variant interpretation and increased accuracy by sharing data","volume":"40","author":"Fokkema","year":"2019","journal-title":"Hum. Mutat."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib45","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8501","article-title":"Association of a polygenic risk score with breast cancer among women carriers of high- and moderate-risk breast cancer genes","volume":"3","author":"Gallagher","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary cancer predisposition syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/gim.2014.48","article-title":"Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations","volume":"16","author":"Garcia","year":"2014","journal-title":"Genet. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/jmedgenet-2019-106759","article-title":"Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network","volume":"57","author":"Garrett","year":"2020","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jmedgenet-2020-107248","article-title":"Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations","volume":"58","author":"Garrett","year":"2021","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13058-020-01328-0","article-title":"Clinical implications of prospective genomic profiling of metastatic breast cancer patients","volume":"22","author":"van Geelen","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/gcc.22919","article-title":"Tumour-only sequencing for oncology management: germline-focused analysis and implications","volume":"60","author":"George","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib53","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/gim.2018.44","article-title":"Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study","volume":"20","author":"Girardi","year":"2018","journal-title":"Genet. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103642_bib54","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib55","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr2919","article-title":"Rare variants in the ATM gene and risk of breast cancer","volume":"13","author":"Goldgar","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","volume":"22","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet. Med."},{"issue":"34","key":"10.1016\/j.critrevonc.2022.103642_bib58","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1200\/JCO.2016.68.6725","article-title":"Multigene panels to evaluate hereditary cancer risk: reckless or relevant?","volume":"34","author":"Hall","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijrobp.2017.05.044","article-title":"Precision oncology and genomically guided radiation therapy: a report from the american society for radiation oncology\/american association of physicists in medicine\/national cancer institute precision medicine conference","volume":"101","author":"Hall","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib61","article-title":"Psychosocial effects of multigene panel testing in the context of cancer genomics","volume":"49","author":"Hamilton","year":"2019","journal-title":"Hastings Cent Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib62","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/humu.24053","article-title":"Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing","volume":"41","author":"Hart","year":"2020","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-019-05487-3","article-title":"Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply","volume":"179","author":"Heemskerk-Gerritsen","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103642_bib65","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1002\/cam4.3427","article-title":"Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: a hereditary cancer registry study","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib66","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10549-020-05895-w","article-title":"Screening women at high risk for breast cancer: one program fits all? Subgroup analysis of a large population high risk breast screening program","volume":"184","author":"Hermann","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2022.103642_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-5-104","article-title":"Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome","volume":"5","author":"Heymann","year":"2010","journal-title":"Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00439-020-02207-6","article-title":"Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients","volume":"140","author":"Horiuchi","year":"2021","journal-title":"Hum. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.critrevonc.2022.103642_bib70","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2017.74.7899","article-title":"Genetic testing: what problem are we trying to solve?","volume":"35","author":"Hughes","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ejhg.2013.85","article-title":"CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer","volume":"22","author":"Huijts","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib72","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41467-020-16141-8","article-title":"High-throughput functional evaluation of BRCA2 variants of unknown significance","volume":"11","author":"Ikegami","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2022.103642_bib73","unstructured":"Ikonopedia. IBIS Risk Assessment Tool [8.0b:[Available from: \u3008https:\/\/ibis.ikonopedia.com\/\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib74","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ajhg.2014.04.009","article-title":"Return of genomic results to research participants: the floor, the ceiling, and the choices in between","volume":"94","author":"Jarvik","year":"2014","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a practical consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jnci\/djy008","article-title":"Testing positive on a multigene panel does not suffice to determine disease risks","volume":"110","author":"Katki","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib78","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/jnci\/djz229","article-title":"CDH1 on multigene panel testing: look before you leap","volume":"112","author":"Katona","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajhg.2020.05.002","article-title":"Management of secondary genomic findings","volume":"107","author":"Katz","year":"2020","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa018","article-title":"Genetic counseling and germline testing in the era of tumor sequencing: a cohort study","volume":"4","author":"Klek","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib81","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1002\/onco.13580","article-title":"Multicenter comparison of molecular tumor boards in The Netherlands: definition, composition, methods, and targeted therapy recommendations","volume":"26","author":"Koopman","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib82","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/s41431-020-00709-5","article-title":"Cancer surveillance for individuals with Li-Fraumeni syndrome","volume":"28","author":"Kratz","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"23","key":"10.1016\/j.critrevonc.2022.103642_bib84","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103642_bib85","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","article-title":"Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer","volume":"35","author":"Kurian","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib86","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","article-title":"Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer","volume":"4","author":"Kurian","year":"2018","journal-title":"JAMA Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103642_bib87","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.20.02785","article-title":"Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019","volume":"39","author":"Kurian","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib88","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/jmedgenet-2019-106072","article-title":"Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1\/2 breast cancer families","volume":"56","author":"Lakeman","year":"2019","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib89","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41436-020-0884-4","article-title":"Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort","volume":"22","author":"Lakeman","year":"2020","journal-title":"Genet. Med."},{"issue":"R2","key":"10.1016\/j.critrevonc.2022.103642_bib90","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1093\/hmg\/ddz187","article-title":"Towards clinical utility of polygenic risk scores","volume":"28","author":"Lambert","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib91","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/humu.23641","article-title":"ClinVar at five years: Delivering on the promise","volume":"39","author":"Landrum","year":"2018","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib92","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib93","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","article-title":"Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels","volume":"21","author":"Lee","year":"2019","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib94","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41436-020-0783-8","article-title":"Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"Li","year":"2020","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib95","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamasurg.2020.6664","article-title":"Bilateral mastectomy in women with unilateral breast cancer: a review","volume":"156","author":"Lim","year":"2021","journal-title":"JAMA Surg."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib96","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19452","article-title":"Yield and utility of germline testing following tumor sequencing in patients with cancer","volume":"3","author":"Lincoln","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib97","article-title":"A breast radiology department-operated, proactive same-day program identifies pathogenic breast cancer mutations in unaffected women","volume":"29","author":"Loving","year":"2022","journal-title":"Acad Radiol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib98","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic` testing for hereditary breast cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103642_bib99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-genom-083118-015253","article-title":"Population screening for inherited predisposition to breast and ovarian cancer","volume":"21","author":"Manchanda","year":"2020","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib100","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib101","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib102","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036269","article-title":"The impact of next-generation sequencing on cancer genomics: from discovery to clinic","volume":"9","author":"Mardis","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib103","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib105","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of variant reclassification following hereditary cancer genetic testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib106","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/ERC-16-0277","article-title":"Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers","volume":"23","author":"Milne","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000469","article-title":"Prospective analysis of 895 patients on a UK genomics review board","volume":"4","author":"Moore","year":"2019","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2012","journal-title":"Fam. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bulcan.2018.08.003","article-title":"The French genetic and cancer consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition","volume":"105","author":"Moretta","year":"2018","journal-title":"Bull. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrclinonc.2017.186","article-title":"The evidence framework for precision cancer medicine","volume":"15","author":"Moscow","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib111","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1245\/s10434-020-08889-6","article-title":"Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing","volume":"27","author":"Murphy","year":"2020","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib112","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)","volume":"26","author":"Naito","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103642_bib113","unstructured":"National Cancer Institute. Breast Cancer Risk Assessment Tool [Available from: \u3008https:\/\/bcrisktool.cancer.gov\/index.html\u3009."},{"key":"10.1016\/j.critrevonc.2022.103642_bib114","unstructured":"National Comprehensive Cancer Network. 2021 [2.2021:[Available from: https:\/\/www.nccn.org\/."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12282-018-0857-5","article-title":"An overview of mammographic density and its association with breast cancer","volume":"25","author":"Nazari","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.critrevonc.2022.103642_bib116","volume":"2","author":"Nielsen","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib118","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamaoncol.2017.0342","article-title":"Multigene panel testing and breast cancer risk: is it time to scale down?","volume":"3","author":"Obeid","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10689-017-0010-1","article-title":"A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting","volume":"17","author":"O'Leary","year":"2018","journal-title":"Fam. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib120","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41436-020-0838-x","article-title":"How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens","volume":"22","author":"O'Shea","year":"2020","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib121","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10689-019-00153-5","article-title":"Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome)","volume":"19","author":"Petry","year":"2020","journal-title":"Fam. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib123","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14737140.2019.1659730","article-title":"An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer","volume":"19","author":"Piccinin","year":"2019","journal-title":"Expert Rev. Anticancer. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib124","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib126","article-title":"From targeting somatic mutations to finding inherited cancer predispositions: the other side of the coin","volume":"9","author":"Pujol","year":"2019","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib127","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41431-018-0224-1","article-title":"Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations","volume":"26","author":"Pujol","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2022.103642_bib128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur. J. Cancer."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib129","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv124","article-title":"Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk","volume":"107","author":"Quante","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaoncol.2019.5963","article-title":"An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review","volume":"6","author":"Rainone","year":"2020","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103642_bib131","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.19.00160","article-title":"The time for mainstreaming germline testing for patients with breast cancer is now","volume":"37","author":"Rajagopal","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib132","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2017.76.0942","article-title":"Genetic testing: multiple problems to solve","volume":"36","author":"Ramos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib133","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/s41436-019-0541-y","article-title":"Genotype-phenotype associations among panel-based TP53+ subjects","volume":"21","author":"Rana","year":"2019","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib134","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2019.1208","article-title":"Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers","volume":"5","author":"Roberts","year":"2019","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib136","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jamaoncol.2019.4004","article-title":"Broad application of multigene panel testing for breast cancer susceptibility-pandora's box is opening wider","volume":"5","author":"Robson","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib137","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib138","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1470-2045(19)30275-X","article-title":"MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial","volume":"20","author":"Saadatmand","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib139","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12920-020-00814-w","article-title":"Study protocol: whole genome sequencing Implementation in standard diagnostics for every cancer patient (WIDE)","volume":"13","author":"Samsom","year":"2020","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.critrevonc.2022.103642_bib141","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.breast.2021.02.003","article-title":"Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability","volume":"56","author":"Scheepens","year":"2021","journal-title":"Breast"},{"issue":"23","key":"10.1016\/j.critrevonc.2022.103642_bib142","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers","volume":"34","author":"Schmidt","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib143","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib144","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/0008-5472.CAN-16-2568","article-title":"BRCA2 hypomorphic missense variants confer moderate risks of breast cancer","volume":"77","author":"Shimelis","year":"2017","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103642_bib146","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/gim.2015.212","article-title":"Improving performance of multigene panels for genomic analysis of cancer predisposition","volume":"18","author":"Shirts","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2022.103642_bib147","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2018.10.007","article-title":"Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations","volume":"106","author":"Singer","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib148","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/L20-0192","article-title":"Different interpretations of the same genetic data","volume":"173","author":"SoRelle","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib149","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/jmedgenet-2012-101037","article-title":"BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk","volume":"49","author":"Spurdle","year":"2012","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/humu.21628","article-title":"ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes","volume":"33","author":"Spurdle","year":"2012","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib151","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","article-title":"Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report","volume":"56","author":"Spurdle","year":"2019","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib152","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djz230","article-title":"Stomaching multigene panel testing: what to do about CDH1?","volume":"112","author":"Stewart","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103642_bib153","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.2019.3893","article-title":"What are polygenic scores and why are they important?","volume":"321","author":"Sugrue","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103642_bib154","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2022.103642_bib155","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","article-title":"Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","volume":"99","author":"Tai","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103642_bib156","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jmedgenet-2017-105188","article-title":"Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK cancer genetics group","volume":"55","author":"Taylor","year":"2018","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010140","article-title":"Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation","volume":"12","author":"Teoh","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib158","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1470-2045(18)30902-1","article-title":"10-year performance of four models of breast cancer risk: a validation study","volume":"20","author":"Terry","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib159","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.prro.2020.04.003","article-title":"ASTRO radiation therapy summary of the ASCO-ASTRO-SSO guideline on management of hereditary breast cancer","volume":"10","author":"Trombetta","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103642_bib161","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103642_bib162","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103642_bib163","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, american society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103642_bib164","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103642_bib165","unstructured":"University of Cambridge. CanRisk Web Tool 2021 [1.2.3 (2021\u201307-05):[Available from: \u3008https:\/\/www.canrisk.org\/\u3009."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103642_bib166","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamasurg.2020.3356","article-title":"Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies","volume":"155","author":"Vos","year":"2020","journal-title":"JAMA Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib167","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jmedgenet-2020-107529","article-title":"Update: variable implementation of the 2018 UKCGG\/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services","volume":"58","author":"Wedderburn","year":"2021","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103642_bib168","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","article-title":"Opportunistic genomic screening. Recommendations of the European Society of Human Genetics","volume":"29","author":"de Wert","year":"2021","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103642_bib169","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10689-018-0070-x","article-title":"Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk","volume":"17","author":"West","year":"2018","journal-title":"Fam. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103642_bib170","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/jmedgenet-2019-106420","article-title":"Germline BRCA1 and BRCA2 testing for breast cancer survivors","volume":"57","author":"Wiggins","year":"2020","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib171","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41416-019-0489-3","article-title":"Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations","volume":"121","author":"Willemsen","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103642_bib172","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/SLA.0000000000002309","article-title":"Indications for contralateral prophylactic mastectomy: a consensus statement using modified delphi methodology","volume":"267","author":"Wright","year":"2018","journal-title":"Ann. Surg."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103642_bib173","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.19.02190","article-title":"Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer","volume":"38","author":"Yadav","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib174","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-020-01260-3","article-title":"Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field","volume":"22","author":"Yanes","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103642_bib175","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103642_bib176","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103642_bib177","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1007\/s13277-013-0830-z","article-title":"Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk","volume":"34","author":"Zhang","year":"2013","journal-title":"Tumour Biol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282200066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282200066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:44:35Z","timestamp":1760903075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282200066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":177,"alternative-id":["S104084282200066X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103642","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103642"}}